13 completed, 7 unknown, 6 not yet recruiting, 6 recruiting. 42 Phase 2, 8 Phase 1, 6 Phase 3.
Follow mFOLFOX6: new trials by email Literature Review of mFOLFOX6 trials Research Report on mFOLFOX6
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Zolbetuximab With mFOLFOX6 or CAPOX in Claudin 18.2 Overexpressed Advanced or Metastatic Biliary Tract Cancers Zolbetuximab, mFOLFOX6, CAPOX - Advanced Biliary Tract Cancer, Metastatic Biliary Tract Carcinoma | Phase 2 | Not yet recruiting | Midhun Malla | 32 | 2026-11-01 | 2026-11-02 |
| mFOLFOXIRI Plus PD-1 Inhibitor vs mFOLFOX6 as Neoadjuvant Therapy for Locally Advanced Colon Cancer cmFOLFOXIRI plus PD-1 inhibitor, mFOLFOX6 - Colon Cancer (Stage II &Amp;Amp; III) | Phase 2 | Not yet recruiting | Sun Yat-sen University | 138 | 2026-10-01 | 2026-05-22 |
| NCT + PD1 + Ketogenic Diet and/or Vitamin C for LARC Short-Course Radiotherapy, PD-1 monoclonal antibody, mFOLFOX6 regimen - Rectal Adenocarcinoma, High-Risk Cancer | Phase 2 | Not yet recruiting | Sixth Affiliated Hospital, Sun Yat-sen University | 100 | 2026-09-01 | 2026-08-14 |
| Total Neoadjuvant mFOLFOX6 Plus Suvemcitug and Enlonstobart With Selective Omission of Pelvic Radiotherapy for High-Risk Mid-Rectal Locally Advanced Rectal Cancer mFOLFOX6, Suvemcitug, Enlonstobart - Rectal Cancer | Phase 2 | Not yet recruiting | Fudan University | 52 | 2026-08-28 | 2026-09-09 |
| Neoadjuvant mFOLFOX6 Chemotherapy Combined With Anti-PD-1 Therapy in MSS/pMMR Locally Advanced Rectal Cancer (FIRM02 Study) mFOLFOX6, Serplulimab - Rectal Cancer | Phase 2 | Not yet recruiting | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | 128 | 2026-02-01 | 2026-02-03 |
| Phase II Open-label Trial of Neoadjuvant Immunochemotherapy for Resectable Non-metastatic Colon cancER: NICER Tecentriq 1200 MG in 20 ML Injection + Capecitabine 1000 mg/m2 + Oxaliplatin 130 mg/m2, Oxaliplatin injection 85mg/m2 + Leucovorin 400mg/m2 + 5-Fluorouracil 2400mg/m2, Oxaliplatin 130mg/m2 + Capecitabine 1000mg/m2 - Stage I Colon Cancer, Stage II Colon Cancer | Phase 2 | Recruiting | Baylor College of Medicine | 28 | 2025-06-15 | 2025-05-25 |
| A Clinical Study to Evaluate the Efficacy and Safety of Envafolimab Combined With Cetuxima-βand mFOLFOX6 in Patients With MSS, RAS/BRAF Wild-Type Metastatic Colorectal Cancer (mCRC) Cetuxima-β, Envafolimab, mFOLFOX6 - Metastatic Colorectal Cancer (CRC) | Phase 2 / Phase 3 | Not yet recruiting | Sun Yat-sen University | 590 | 2025-06-01 | 2025-05-06 |
| SCRT+mFOLFOX6+PD-1 Antibody and Targeted Therapy for High-Risk pMMR/MSS Rectal Cancer Short-Course Radiotherapy, PD-1 monoclonal antibody, mFOLFOX6 regimen - Rectal Adenocarcinoma, High-Risk Cancer | Phase 2 | Completed | Sixth Affiliated Hospital, Sun Yat-sen University | 49 | 2025-04-02 | 2026-08-04 |
| Neoadjuvant FOLFIRINOX and Preoperative Chemoradiotherapy for Locally Advanced Rectal Cancer Patients mFOLFIRINOX, mFolfox6 - Rectum Cancer | Phase 2 | Recruiting | Menoufia University | 100 | 2025-01-25 | 2025-02-19 |
| Cadonilimab Combination Regimen as First-line Treatment for HER2-expressing GC/GEJ Patients cadonilimab, Trastuzumab, XELOX - Metastatic HER2 Positive Gastroesophageal Junction Cancer | Phase 1 / Phase 2 | Recruiting | Zhejiang Cancer Hospital | 90 | 2024-07-10 | 2024-10-21 |
| Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread Zongertinib, Trastuzumab deruxtecan, Trastuzumab emtansine - Metastatic Breast Cancer, Metastatic Gastric Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | Boehringer Ingelheim | 910 | 2024-06-28 | 2026-11-16 |
| Total Neoadjuvant Therapy in Rectal Cancer Short-course radiotherapy, mFOLFOX6 - Rectal Cancer | Phase 2 | Recruiting | National Cheng-Kung University Hospital | 42 | 2023-11-16 | 2026-04-08 |
| Neoadjuvant Treatment With mFOLFOXIRI Plus Cadonilimab (AK104) Versus mFOLFOX6 in Locally Advanced Colorectal Cancer mFOLFOXIRI + Cadonilimab, mFOLFOX6, mFOLFOXIRI - Colorectal Cancer | Phase 2 | Recruiting | Sun Yat-sen University | 143 | 2023-07-10 | 2025-07-23 |
| Neoadjuvant Cadonilimab Plus Chemotherapy Following Short-Course Radiotherapy in Locally Advanced Rectal Cancer Cadonilimab Injection, Short-course radiotherapy, Consolidation chemotherapy - Locally Advanced Rectal Carcinoma | Phase 2 | Completed | Shenzhen People's Hospital | 27 | 2023-04-11 | 2025-02-05 |
| The Efficacy and Safety of Fruquintinib Plus FOLFIRI/FOLFOX as Second-line Treatment in Patients With RAS-mutant Metastatic Colorectal Cancer Fruquintinib, FOLFIRI, mFOLFOX6 - Metastatic Colorectal Cancer | Phase 2 | Unknown | Fudan University | 68 | 2022-12-01 | 2022-12-02 |
| Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07+HLX10 +mFOLFOX6 or HLX07 Monotherapy in Patients With mCRC HLX07, HLX10, mFOLFOX6 - CRC | Phase 2 | Unknown | Shanghai Henlius Biotech | 50 | 2022-07-15 | 2022-05-03 |
| Cetuximab Maintenance Treatment Versus Continuation After Induction Therapy in mCRC Cetuximab, mFOLFOX6, FOLFIRI - Colorectal Cancer | Phase 2 / Phase 3 | Unknown | Ruijin Hospital | 200 | 2021-11-01 | 2021-04-30 |
| Neoadjuvant Therapy for Localized Rectal Adenocarcinoma Chemoradiation, short course radiation therapy, mFOLFOX6 - Rectal Adenocarcinoma | Phase 2 | Withdrawn | UNC Lineberger Comprehensive Cancer Center | 2021-08-13 | 2021-11-10 | |
| A Trial of Durvalumab (MEDI 4736) in Combination With Extended Neoadjuvant Regimens in Rectal Cancer Durvalumab, FOLFOX, Short Course Radiotherapy (Arm A) - Rectal Cancer, Rectal Adenocarcinoma | Phase 2 | Unknown | Liz-Anne Lewsley | 48 | 2020-12-07 | 2020-11-09 |
| Preoperative Sequential Short-course Radiation Therapy and FOLFOX for Locally Advanced Rectal Cancer short-course radiotherapy, mFOLFOX6, Chemoradiotherapy - Rectal Cancer | Phase 2 | Active not recruiting | Kyungpook National University Hospital | 364 | 2020-10-23 | 2026-02-12 |
Showing 20 of 42. Sign in to see all of them.
Colorectal Neoplasms (15) · Rectal Neoplasms (14) · Colonic Neoplasms (5) · Neoplasm Metastasis (3) · Stomach Neoplasms (3) · Pancreatic Neoplasms (2) · Adenocarcinoma (1) · Adenocarcinoma Of Esophagus (1) · Breast Neoplasms (1) · Carcinoma, Hepatocellular (1) · Cold Hypersensitivity (1) · Esophageal Neoplasms (1) · Fowlpox (1) · Neuralgia (1) · Neuropathy, Painful (1)
Sun Yat-sen University (4) · Amgen (2) · Fudan University (2) · Ruijin Hospital (2) · Sixth Affiliated Hospital, Sun Yat-sen University (2) · ASLAN Pharmaceuticals (1) · AVEO Pharmaceuticals, Inc. (1) · Aadi Bioscience, Inc. (1) · Baruch Brenner (1) · Baylor College of Medicine (1) · Boehringer Ingelheim (1) · Five Prime Therapeutics, Inc. (1) · Gustave Roussy, Cancer Campus, Grand Paris (1) · Hoosier Cancer Research Network (1) · Kyungpook National University Hospital (1)
United States (18) · China (13) · Belgium (5) · Italy (5) · South Korea (5) · Spain (5) · United Kingdom (5) · France (4) · Germany (4) · Australia (3) · Canada (3) · Hungary (3) · Japan (3) · Taiwan (3) · Thailand (2)
Atif Iqbal, MD (1) · Baruch Brenner, Prof (1) · Charlie Qi, MD (1) · Guohui Wan, PhD. (1) · Jieer Ying, MD (1) · Juan Huang, PhD. (1) · Jun Huang, PhD. (1) · Jun Zhang, MD & Ph.D (1) · Michael S Lee, MD (1) · Midhun Malla, MD, MS (1) · Norman Wolmark, MD (1) · Patrick Boland, M.D. (1) · Peng Junjie (1)
PMID 24457377, PMID 26032776, PMID 26049686, PMID 26109878, PMID 30081865, PMID 32965540, PMID 33207247, PMID 34446053, PMID 36244398, PMID 36852723, PMID 37923987, PMID 38084840, PMID 38308771, PMID 38309722, PMID 41108088, PMID 42134324
2014 (1), 2016 (1), 2017 (1), 2019 (1)